HC Wainwright Issues Pessimistic Outlook for LBRX Earnings

LB Pharmaceuticals Inc (NASDAQ:LBRX) – Stock analysts at HC Wainwright lowered their Q2 2026 earnings per share (EPS) estimates for shares of LB Pharmaceuticals in a research note issued to investors on Tuesday, May 26th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings per share of ($0.77) for the quarter, down from their previous estimate of ($0.73). HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for LB Pharmaceuticals’ current full-year earnings is ($3.55) per share. HC Wainwright also issued estimates for LB Pharmaceuticals’ Q3 2026 earnings at ($0.97) EPS, FY2026 earnings at ($3.61) EPS, Q1 2027 earnings at ($1.25) EPS, Q2 2027 earnings at ($1.29) EPS, Q4 2027 earnings at ($1.41) EPS and FY2027 earnings at ($5.30) EPS.

LB Pharmaceuticals (NASDAQ:LBRX) last issued its quarterly earnings results on Tuesday, May 12th. The company reported ($0.67) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.75) by $0.08.

Several other brokerages have also recently issued reports on LBRX. Craig Hallum started coverage on LB Pharmaceuticals in a research report on Friday, April 10th. They set a “buy” rating and a $36.00 price target on the stock. Stifel Nicolaus lifted their price target on LB Pharmaceuticals from $35.00 to $40.00 and gave the company a “buy” rating in a research report on Friday, March 27th. Finally, Roth Mkm restated a “buy” rating and issued a $37.00 target price on shares of LB Pharmaceuticals in a report on Sunday, May 17th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, LB Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $38.40.

LB Pharmaceuticals Stock Performance

Shares of LBRX stock opened at $27.80 on Thursday. LB Pharmaceuticals has a 1 year low of $13.36 and a 1 year high of $33.47. The stock has a market cap of $797.30 million and a PE ratio of -16.07. The business’s fifty day moving average is $28.00 and its 200-day moving average is $23.50.

Hedge Funds Weigh In On LB Pharmaceuticals

A number of hedge funds have recently modified their holdings of the stock. California State Teachers Retirement System acquired a new stake in shares of LB Pharmaceuticals in the fourth quarter worth $26,000. Russell Investments Group Ltd. acquired a new stake in shares of LB Pharmaceuticals in the fourth quarter worth $34,000. Bank of America Corp DE acquired a new stake in shares of LB Pharmaceuticals in the third quarter worth $27,000. Strs Ohio acquired a new stake in shares of LB Pharmaceuticals in the fourth quarter worth $76,000. Finally, Persistent Asset Partners Ltd acquired a new stake in shares of LB Pharmaceuticals in the fourth quarter worth $91,000.

LB Pharmaceuticals Company Profile

We are a clinical-stage biopharmaceutical company developing novel therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. We are building a pipeline that leverages the broad therapeutic potential of our lead product candidate, LB-102, which we believe has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is a new chemical entity and a methylated derivative of amisulpride, a second-generation antipsychotic drug approved in over 50 countries, not including the United States, because the development and regulatory requirements of the U.S.